This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

A guide to KEYTRUDA® (pembrolizumab) and how to manage immune-related adverse events

Prescribing Information

Download this slide deck for information on the MOA of KEYTRUDA® (pembrolizumab), dosing and administration and the management of immune-related adverse events.

More information about KEYTRUDA® (pembrolizumab):

Supporting documentation

GB-PDO-01468 | Date of Preparation: February 2021